Syneron Bio
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Syneron Bio - overview
Established
2025
Location
Beijing, -, China
Primary Industry
Biotechnology
About
Based in Beijing, China and founded in 2025, Yuansi Biopeptide (Beijing) Technology Co. , Ltd. , trading as Syneron Bio, is a biotechnology company dedicated to developing novel macrocyclic peptide drugs. In March 2026, Syneron Bio closed USD 150 million in Series B funding co-led by Decheng Capital, CDH Investments and other investor, Sinovation Ventures, 5Y Capital, GL Ventures, Lenovo Capital and Incubator Group, Abu Dhabi Investment Authority, True Light Capital, Qiming Venture Partners, BioTrack Capital, Lilly Asia Ventures, Biotech Development Fund, and other investors.
The company utilizes its unique Synova™ platform technology to build a rich and differentiated pipeline of macrocyclic peptide drugs, providing breakthrough treatment solutions for global oncology, autoimmune diseases, and rare diseases. The company generates revenue by developing and providing novel macrocyclic peptide drugs and other related services.
Current Investors
5Y Capital, Sinovation Ventures, China International Capital Corporation
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Biotechnology, Oncology/Cancer Treatment
Verticals
Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.